Arcadia Biosciences (NASDAQ:RKDA) Upgraded at ValuEngine

ValuEngine upgraded shares of Arcadia Biosciences (NASDAQ:RKDA) from a sell rating to a hold rating in a report issued on Thursday morning, ValuEngine reports.

Several other research analysts also recently commented on the company. National Securities restated a buy rating and set a $15.00 price objective on shares of Arcadia Biosciences in a report on Thursday, May 9th. HC Wainwright restated a buy rating and set a $14.00 price objective (down from $20.00) on shares of Arcadia Biosciences in a report on Thursday, June 6th.

Shares of NASDAQ RKDA remained flat at $$2.02 during midday trading on Thursday. The stock had a trading volume of 103,332 shares, compared to its average volume of 122,257. The company has a quick ratio of 6.19, a current ratio of 6.26 and a debt-to-equity ratio of 2.80. The company has a 50-day simple moving average of $3.10. Arcadia Biosciences has a 12-month low of $1.90 and a 12-month high of $10.40. The company has a market cap of $12.66 million, a price-to-earnings ratio of -0.38 and a beta of -2.01.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings results on Wednesday, May 8th. The basic materials company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.63). The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.40 million. Arcadia Biosciences had a negative return on equity of 178.78% and a negative net margin of 1,099.22%. Sell-side analysts expect that Arcadia Biosciences will post -4.62 earnings per share for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

See Also: Golden Cross

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with's FREE daily email newsletter.